Clinical trial · Interventional
A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 Clinical Study to Investigate the Safety, Tolerability and Efficacy of HLX60 (Anti-GARP Monoclonal Antibody) Combination With HLX10 (Anti-PD-1 Monoclonal Antibody) in Subjects With Advanced or Metastatic Solid Tumors
NCT05483530CI-TRIAL-00076091unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the safety and tolerability of HLX60 combined with HLX10 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy for each combination regimen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced or Metastatic Solid Tumors | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HLX60 combined with HLX10 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HLX60 combined with HLX10
- interventionNames
- Biological: HLX60 combined with HLX10
Primary outcomes (4)
- measure
- Adverse event
- timeFrame
- Through study completion, assessed up to 2 years.
- description
- Incidence and severity of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 for patients receiving study drug.
- measure
- Incidence of DLT
- timeFrame
- Up to 3 weeks.
- description
- Ratio of the number of patients with DLT events in each dose group to the number of patients in the dose group during the DLT evaluation period.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically or cytologically confirmed advanced malignant solid tumor, who have failed or cannot receive the standard treatment; * With at least one evaluable lesion according to RECIST v1.1 (for solid tumors); * Patients must be able to supply adequate tumor tissue for biomarker (including the expression of PD-L1, GARP) analyses; * Life expectancy longer than three months; * Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. Exclusion Criteria: * Has a concurrently active second malignancy, other than adequately treated non-melanoma skin cancers, in situ melanoma or in situ cervical cancer. Participants with history of the second malignancy have been disease-free for \<3 years. * Has a history of (non-infectious) interstitial lung disease (ILD) that required steroids, currently has ILD, or when suspected ILD cannot be ruled out by imaging at screening. * Participant has unresolved AEs ≥ Grade 2 from prior anticancer therapy except for alopecia. * Those who have received anti-GARP or anti-GARP/TGFβ complex antibody therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.